The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Overview of Market Growth

• The angina market has shown strong growth, increasing from $10.11 billion in 2023 to $10.71 billion in 2024 at a CAGR of 5.9%.
• This growth is driven by factors such as the rising prevalence of coronary heart disease, increased use of vasodilators, and advancements in diagnostic capabilities.
• The market is projected to continue its upward trajectory, reaching $13.61 billion by 2028, with a CAGR of 6.2%.

Factors Driving Growth

• Prevalence of Coronary Artery Disease (CAD):
  • The increasing cases of CAD, caused by lifestyle changes and genetic factors, are fueling the demand for angina treatments.
  • Angina is critical for diagnosing CAD, guiding treatment, and informing public health strategies.
• Advancements in Diagnosis and Treatment:
  • Improved diagnostic techniques, including advanced imaging, have enhanced the detection and management of angina.
  • Technological advancements in angioplasty, stenting, and gene therapy are contributing to better outcomes for patients.
• Rising Demand for Medications:
  • Growing awareness of cardiovascular health has increased the demand for medications, particularly in retail pharmacy settings.
  • The market is seeing significant interest in beta blockers, nitrates, calcium channel blockers, and ACE inhibitors.

View More On The Angina Market Report 2024 – https://www.thebusinessresearchcompany.com/report/angina-global-market-report

Key Market Trends

• Technological Innovations:
  • Early diagnosis is being revolutionized by new imaging techniques, helping healthcare providers detect angina and related conditions more efficiently.
  • Advancements in angioplasty and stenting are making these procedures safer and more effective.
• Emerging Treatments:
  • New gene therapy approaches are being explored to provide targeted treatments for patients with coronary artery disease.
  • The demand for coronary stents is rising, driven by the increasing number of angioplasty procedures.

Market Players and Innovations

• Leading Companies:
  • Major players in the angina market include Pfizer Inc., Johnson & Johnson, Merck & Co Inc., Bayer AG, Sanofi S.A., Novartis AG, and AstraZeneca PLC.
  • These companies are focusing on developing innovative treatments to address the growing burden of angina and related cardiovascular conditions.
• Metoprolol Tartrate Tablets:
  • Pharmaceutical companies are introducing new medications, such as metoprolol tartrate tablets, to enhance the treatment of angina and CAD.
  • Zydus received FDA approval in April 2023 to market generic metoprolol tartrate tablets, which are used to treat hypertension and angina.

Strategic Acquisitions

• Novo Nordisk’s Acquisition of Cardior Pharmaceuticals:
  • In March 2024, Novo Nordisk acquired Cardior Pharmaceuticals for $1.10 billion, aiming to strengthen its cardiovascular disease portfolio.
  • Cardior’s RNA-based therapeutics, particularly CDR132L for heart failure, are expected to play a significant role in Novo Nordisk’s future offerings.

Regional Insights

• North America:
  • North America was the largest market for angina in 2023, driven by advanced healthcare infrastructure and high prevalence of CAD.
• Asia-Pacific:
  • Asia-Pacific is expected to be the fastest-growing region in the coming years, driven by increasing awareness of cardiovascular health and rising healthcare investments.

Conclusion

• The angina market is poised for continued growth, driven by the rising prevalence of coronary artery disease, technological advancements, and strategic initiatives by key players.
• With a focus on innovation and expanding treatment options, the market is set to offer significant opportunities for companies and healthcare providers in the years ahead.

Request A Sample Of The Global Angina Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=16337&type=smp